| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Olaparib |
| Brand | Lynparza® |
| Indication | As monotherapy for the maintenance treatment of adult patients with BRCA-mutated platinum sensitive relapsed ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy. This is a sub-group of the entire licensed population. |
| Assessment Process | |
| Rapid review commissioned | 23/07/2019 |
| Rapid review completed | 06/08/2019 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that olaparib not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
